Vicore Pharma Holding AB (publ) (“Vicore”), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today announces that the U.S. Patent and Trademark Office (USPTO) has granted patent number US11,123,329 covering the use of C21 to treat infections caused by Severe Acute Respiratory Syndrome (SARS) coronavirus (CoV), including SARS-CoV-2.
Read MoreVicore Pharma Holding AB, a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces the addition of three experienced executives to its management team, strengthening business and commercial operations as the company’s research and development activities approach key commercial decision points.
Read More
